STOCK TITAN

Teleflex Incorporated - TFX STOCK NEWS

Welcome to our dedicated news page for Teleflex Incorporated (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex Incorporated.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teleflex Incorporated's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teleflex Incorporated's position in the market.

Rhea-AI Summary
Liam Kelly, CEO of Teleflex, to speak at Morgan Stanley conference on Sep 13. Live webcast available on teleflex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
-
Rhea-AI Summary
Teleflex announces release of Arrow ErgoPack Complete Kits with Hemodialysis and Large Bore catheters in the US, streamlining insertion workflow for clinicians and providing more options. Expansion includes clinician-inspired updates and meets recommendations of CDC, SHEA, INS, and OSHA guidelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) declares $0.34 quarterly cash dividend, payable on September 15, 2023, to shareholders of record on August 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
dividends
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announced Q2 2023 financial results, with revenues of $743.3 million, up 5.5% YoY, and diluted EPS of $2.35. The company raised its 2023 revenue growth guidance to 5.80% to 6.55% and maintained adjusted diluted EPS guidance of $13.00 to $13.60. The acquisition of Palette Life Sciences AB is expected to contribute meaningfully to growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announces FDA clearance for expanded use of QuikClot Control+™ Hemostatic Device in cardiac surgical procedures, offering a new solution for intraoperative bleeding control. The device also received expanded intended uses to include patients on anticoagulation/antiplatelet medication, use with or without autotransfusion equipment, and use with or without cardiopulmonary bypass systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
-
Rhea-AI Summary
Teleflex Incorporated announces acquisition of Palette Life Sciences AB for $600 million, expanding its Interventional Urology portfolio. The acquisition includes the biodegradable rectal spacer Barrigel®, which reduces radiation during prostate cancer therapy. The transaction is expected to be completed in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announced three group purchasing agreements with Premier, Inc. for select medical products, allowing Premier members to access special pricing and terms for Laryngoscope Systems, Laryngeal Masks Airways, and Disposable Anesthesia Products. The agreements aim to provide healthcare providers with solutions to optimize patient outcomes and improve care quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary
Teleflex Incorporated (NYSE:TFX) will host a conference call on August 3, 2023, to discuss its second quarter financial results and provide an operational update. Participants can pre-register and receive dial-in information. The call will be accessible via live audio webcast on teleflex.com. An audio replay will be available on the company's website or by telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) completes patient enrollment in the Ringer™ PTCA study, evaluating the performance of the Ringer™ Perfusion Balloon Catheter in patients undergoing Percutaneous Coronary Interventions. The study, led by Principal Investigator Kathleen Kearney M.D., aims to validate the device's clinical efficacy and regulatory pathway for release. Completion of enrollment marks a significant milestone in the development of the Ringer™ Perfusion Balloon Catheter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
Teleflex Incorporated

NYSE:TFX

TFX Rankings

TFX Stock Data

10.10B
46.91M
0.26%
98.54%
1.89%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Wayne

About TFX

teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. headquartered in wayne, pa, teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.